There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sensus Healthcare (SRTS – Research Report) and Oncolytics Biotech (ONCY – Research Report) with bullish sentiments.
Sensus Healthcare (SRTS)
In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Sensus Healthcare. The company’s shares closed last Friday at $1.90.
According to TipRanks.com, Vendetti is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Sensus Healthcare is a Strong Buy with an average price target of $4.50, implying a 143.2% upside from current levels. In a report released yesterday, Alliance Global Partners also reiterated a Buy rating on the stock with a $4.00 price target.
See the top stocks recommended by analysts >>
Oncolytics Biotech (ONCY)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Oncolytics Biotech yesterday and set a price target of $5.00. The company’s shares closed last Friday at $1.45, close to its 52-week low of $1.09.
According to TipRanks.com, McCarthy has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oncolytics Biotech with a $7.17 average price target, which is a 435.1% upside from current levels. In a report issued on November 3, JonesTrading also maintained a Buy rating on the stock with a C$9.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SRTS:
- Sensus Healthcare reports Q3 EPS (9c), consensus (2c)
- Sensus Healthcare Reports Third Quarter 2023 Financial Results
- SRTS Upcoming Earnings Report: What to Expect?
- Sensus Healthcare to Host Third Quarter 2023 Financial Results and Business Update Conference Call on Thursday, November 9, 2023
- Sensus Healthcare to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference
